A bit like immunotherapy 5 years ago or sir spheres 10 years ago..
Wealthy private payers/charity etc
Then special ex gratia requests or high cost drug requests to governments or private health funds
Then private health fund coverage
Then government coverage.
If oncosil replaces other radiotherapy, then there is a cost offset argument.
The fact that pancreatic cancer isn't that common and there are few options strengthens the exgratia funding argument
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |